AUS
NZ
UK
CA
USA
IND
Clarity Pharmaceuticals Ltd (ASX:CU6), a clinical-stage company specializing in copper theranostics, has submitted an application to the ASX for the quotation of 110,000 new fully paid ordinary shares. These shares were issued on 1 July 2026 after the exercise of options from the CU6AAM class at an exercise price of $0.508 each. Following this issuance, Clarity's total quoted ordinary shares now stand at 373,081,230, with 20,094,797 options of the same class still unexercised and unquoted. This update offers investors a clear view of Clarity's capital structure and potential dilution at the start of the new financial year.
Key Points
- Company: Clarity Pharmaceuticals Ltd (ASX:CU6)
- 110,000 fully paid ordinary shares issued on 1 July 2026 following option conversion
- Options exercised from CU6AAM class at AUD $0.508 per share
- Total quoted ordinary shares after issuance: 373,081,230
- Outstanding unquoted CU6AAM options: 20,094,797
- New shares rank equally with existing ordinary shares from the issue date
- Investors should monitor further exercises of the remaining CU6AAM options
Conversion of 110,000 CU6AAM Options on 1 July 2026
Clarity Pharmaceuticals confirmed that 110,000 options from the CU6AAM class, described as "Options Expiring Various Dates Ex Various Prices," were exercised and converted into fully paid ordinary shares on 1 July 2026. Both the first and last exercise dates recorded were the same, indicating a single transaction or batch exercise on that day.
The converted shares belong to the existing CU6 ordinary share class, with no new security class created. The filing states these newly issued shares are intended for ASX quotation but were not yet quoted at the announcement date. Once approved, these shares will trade alongside existing ordinary shares, ranking equally from the issue date of 1 July 2026.
Exercise Price of $0.508 Per Share and Cash Proceeds
The 110,000 shares were issued at an exercise price of AUD $0.508 each, resulting in gross proceeds of approximately $55,880. The payment was made in Australian dollars. The company did not provide further details on the use of these proceeds or a breakdown beyond the exercise price.
This exercise price reflects the rate at which option holders converted their options into equity. Investors may consider whether this price was at a premium or discount to the prevailing market price at the time, although no immediate share price impact was publicly available.
Impact on Clarity Pharmaceuticals’ Total Share Count
After the quotation of these 110,000 shares, the total quoted ordinary shares of Clarity Pharmaceuticals will increase to 373,081,230. This figure is generated by the ASX system based on lodged forms and may not reflect the current issued capital if other forms are pending.
For shareholders and analysts, this addition is a minor increase to the total share pool. However, with 20,094,797 CU6AAM options still outstanding and unquoted, further option exercises could incrementally increase the share count.
Outstanding CU6AAM Options Number 20,094,797
The filing reveals that 20,094,797 CU6AAM options remain unexercised and unquoted following this transaction. These options have various expiry dates and exercise prices. Holders retain the right to convert these options into ordinary shares in the future, subject to their terms.
From a dilution perspective, these remaining options represent a significant potential overhang relative to the current quoted share base. If fully exercised, they could increase the share count by approximately 5.4% over the current 373,081,230 shares, although actual exercises depend on market conditions and option terms. The filing did not disclose expiry dates or exercise prices for these remaining options.
Options Issued Under Employee Incentive Scheme
The exercised options were issued under an employee incentive scheme, a common practice among ASX-listed biotech and pharmaceutical companies. Such schemes grant options to employees, executives, and eligible participants as part of remuneration and retention strategies, often with vesting schedules and exercise windows.
The filing also notes that the exercised options are held by key management personnel (KMP) or associates. This is relevant for governance-focused investors, as KMP option exercises require disclosure under ASX Listing Rules and may indicate insider views on company prospects. However, the specific KMP involved were not named, and no management commentary was provided regarding the timing of the exercise.
New Shares Rank Equally With Existing CU6 Ordinary Shares
Clarity Pharmaceuticals confirmed that the 110,000 new shares rank equally in all respects with existing CU6 ordinary shares from their issue date of 1 July 2026. This grants the new shareholders the same rights, including participation in dividends, capital returns, and voting.
Equal ranking from the date of issue is standard for shares issued via option conversion on the ASX. The confirmation in the Appendix 2A filing provides regulatory clarity, allowing investors to treat these shares as fully equivalent once ASX grants quotation.
Capital Structure Snapshot at the Start of FY2026
This update, dated 1 July 2026—the first day of the Australian financial year—offers a benchmark of Clarity Pharmaceuticals’ capital structure. With 373,081,230 quoted ordinary shares and 20,094,797 unquoted options outstanding, investors have a clearer understanding of the company’s potential fully diluted share count as FY2026 begins.
Clarity Pharmaceuticals develops targeted copper theranostics, combining therapeutic and diagnostic applications using copper-based radiopharmaceuticals. The company is advancing several clinical programs, and its capital management activities, including option exercises, are part of maintaining its listed equity structure. No operational or clinical updates were provided in this filing.
Future Dilution Risk From Remaining CU6AAM Options
With 20,094,797 CU6AAM options still outstanding with various expiry dates and exercise prices, investors should anticipate further Appendix 2A filings as option holders exercise their rights. Each exercise will incrementally raise the ordinary share count and generate cash proceeds for the company at the respective exercise prices. The total proceeds if all options were exercised depend on the mix of exercise prices, which was not disclosed.
For a clinical-stage company like Clarity Pharmaceuticals, which is not yet generating commercial revenue, option exercises provide a supplementary source of liquidity alongside capital raises. Although dilutive, these exercises bring cash inflows at predetermined prices. The company did not offer guidance on expected future exercises or cash receipts.
Monitoring Future CU6AAM Option Exercises
Investors tracking the remaining 20,094,797 CU6AAM options should monitor Clarity Pharmaceuticals’ future Appendix 2A filings on the ASX announcements platform. These filings will detail the number of options exercised, issue dates, and updated issued capital. They are typically lodged promptly after exercise events, providing transparency on changes to the share structure.
Additionally, exercises by KMP will be disclosed in corporate governance documents such as director’s interest notices (Appendix 3Y) and the annual remuneration report. For investors using KMP activity as an insider sentiment indicator, these disclosures offer valuable insights beyond capital structure updates. The next key event to watch is whether further option exercises occur before the remaining CU6AAM options expire, although expiry details were not provided in this update.
